Extracellular vesicles (EVs) are tiny particles secreted by cells that mediate intercellular communication and regulate immune responses. By carrying microRNAs, proteins, and lipids, EVs spread cellular senescence and promote the senescence-associated secretory phenotype (SASP), creating a cycle of "senescence-inflammation-dysfunction". In a recent review, researchers from China elaborate how EVs mediate cellular senescence in multiple chronic lung diseases. It also discusses the advances, existing challenges, and translational prospects of EV-based therapies for these aging-related pulmonary diseases.

A nationwide survey of 130 Chinese pancreatic surgeons finds that perioperative nutrition management for pancreatoduodenectomy has improved substantially since 2020. Preoperative nutritional assessment rose from 62.5% to 82.3% and dietitian involvement from 49.0% to 70.0%. However, total parenteral nutrition on the first postoperative day remained high at 52.3%, while early oral feeding was only 16.2%.

A small but carefully documented retrospective case series from a US pulmonary hypertension clinic reports that nebulized ensifentrine an inhaled dual phosphodiesterase 3/4 inhibitor approved in 2024 for moderate-to-severe COPD, was associated with modest but consistent improvements in pulmonary hemodynamics, exercise capacity, and patient-reported breathlessness over six months in patients with severe COPD-associated pulmonary hypertension, without provoking exacerbations, worsening oxygenation, or significant adverse events. To the authors' knowledge, this is the first published report evaluating ensifentrine specifically in patients with COPD-associated pulmonary hypertension confirmed by right heart catheterization.